Prediction of the Chronicization of Radiation-induced Acute Intestinal Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-01

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our team has constructed a prediction model based on the expression level of immune factors (PD-L1, PD-1, CTLA4, Siglec15) to predict the chronicization of radiation-induced acute intestinal injury (RAII) and verified the predictive efficacy of the system in retrospective studies. This clinical study intends to further prospectively verify the accuracy of this prediction model in rectal cancer patients. In this study, we plan to enroll 200 patients diagnosed with locally advanced rectal cancer by pathology and MRI, who undergo neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME) and develop RAII during NCRT or within 1 month. We will follow up the occurrence and progression of radiation-induced intestinal injury within 1 year after TME. Expression levels of immune factors will be detected in pathological tissue after TME and applied to the prediction model to predict the chronicization of RAII. Based on the clinical diagnosis of chronic radiation-induced intestinal injury, the area under curve (AUC), accuracy, precision, specificity, and sensitivity of this prediction model in predicting the chronicization of RAII will be evaluated. The main outcome hypothesis is that the AUC of chronicization of RAII predicted by the prediction model based on the expression level of immune factors is more than 0.8.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prediction of the Chronicization of Radiation-induced Acute Intestinal Injury Based on the Expression Level of lncRNA

NCT05749497

Radiation-induced Intestinal Injury

NOT_YET_RECRUITING

Prediction of Radiation-induced Late Intestinal Injury

NCT05749510

Radiation-induced Intestinal Injury

NOT_YET_RECRUITING

Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer

NCT06493240

Locally Advanced Rectal Cancer

COMPLETED PHASE2

Sigmoid Colon Organ Motion in Radiotherapy

NCT03259828

Sigmoid Cancer Sigmoid Colon Cancer

COMPLETED NA

Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer

NCT06375434

Locally Advanced Rectal Cancer

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design and setting The study is a prospective, observational, confirmatory, single-center study in predicting the chronicization of radiation-induced acute intestinal injury based on the expression level of immune factors.

Participants Patients diagnosed with locally advanced rectal cancer, who undergo NCRT and TME at The Sixth Affiliated Hospital, Sun Yat-sen University and develop RAII during NCRT or within 1 month will be assessed for suitability for inclusion.

Inclusion criteria Written informed consent. 18-75 years of age. ECOG score for performance status is 0-2. Locally advanced rectal adenocarcinoma (T3-4/N+M0) with pathological and MRI diagnosis. Patient will undergo NCRT and TME therapies and develop RAII during NCRT or within 1 month.

Exclusion criteria Patients with other active malignant tumors. Patients who have received pelvic radiotherapy or immunotherapy. Pathological tissue cannot be obtained after TME. Patients with toxicity (CTCAE Grade ≥ 2) caused by previous treatment that has not subsided. Pregnant or lactating women.

Interventions The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.

Outcomes The primary outcome is the AUC of chronicization of RAII predicted by the prediction model. The secondary outcomes are accuracy, precision, specificity, and sensitivity of this prediction model in predicting chronicization of RAII.

Recruitment Patients aged 18-75 years who have been diagnosed with locally advanced rectal cancer and consider NCRT+TME therapies and develop RAII during NCRT or within 1 month are eligible for the study. The study physicians will inform the patients about the study in detail. After obtaining informed consent, the patient is recruited to the study. We will follow up the occurrence and progression of radiation-induced intestinal injury within 1 year after TME. Expression levels of immune factors will be detected in pathological tissue after TME and applied to the prediction model to predict the chronicization of RAII.

Participant timeline Recruitment started in March 1, 2023 at The Sixth Affiliated Hospital, Sun Yat-sen University.

Sample size We plan to enroll 200 patients diagnosed with locally advanced rectal cancer by pathology and MRI, who undergo NCRT and TME and develop RAII during NCRT or within 1 month.

Data management, collection and monitoring All protocol-required information collected during the study will be entered by the investigator in the electronic case report forms (CRF). The investigator should complete the CRF as soon as possible after information is collected. An explanation should be given for all missing data. The completed CRF will be reviewed and signed by the investigator. The main investigator will continuously monitor data. Data will be stored in the secured network of Sun Yat-sen University and for security reasons, in an external hard drive which will be used to back up regularly the database.

Statistical methods For statistical analysis of the quantitative variables with normal distribution, the mean, standard deviation (SD), median and interquartile range will be calculated. Group comparisons will be made using t tests or Mann-Whitney U test for continuous variables. Associations between the categorical variables will be tested with the Chi-Square-test or the Fisher exact test, when appropriate. Paired values (before and after therapies) will be compared for each patient using a paired t test or a Wilcoxon test. The data will be analyzed using IBM SPSS Statistics for Windows, version 27.0 (IBM Corporation, Armonk, NY, USA). A significance threshold of p \< 0.05 will be adopted for all tests.

Research ethic approval The study adheres to the Declaration of Helsinki on medical research protocols and ethics. The protocol was reviewed and approved by the Human Medical Ethics Committee of the Sixth Affiliated Hospital of Sun Yat-sen University (2023ZSLYEC-075).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Radiation-induced Intestinal Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NCRT+TME

Neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME) Interventions

NCRT+TME

Intervention Type OTHER

The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NCRT+TME

The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent. 18-75 years of age. ECOG score for performance status is 0-2. Locally advanced rectal adenocarcinoma (T3-4/N+M0) with pathological and MRI diagnosis. Patient will undergo NCRT and TME therapies and develop RAII during NCRT or within 1 month.

Exclusion Criteria

* Patients with other active malignant tumors. Patients who have received pelvic radiotherapy or immunotherapy. Pathological tissue cannot be obtained after TME. Patients with toxicity (CTCAE Grade ≥ 2) caused by previous treatment that has not subsided. Pregnant or lactating women.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No